Immunomedics, Inc. (IMMU)
(Delayed Data from NSDQ)
$14.74 USD
-0.16 (-1.07%)
Updated May 3, 2019 04:00 PM ET
After-Market: $14.75 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[IMMU]
Reports for Purchase
Showing records 21 - 40 ( 68 total )
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
TRODELVY Gets FDA Green Light Ahead of Schedule; Raising Target to $60
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
ASCENT Trial Halted Early Based on Impressive Efficacy; Raising PT to $34
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Despite Another Form 483, Delay Beyond 12 Months Appears Unlikely; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
2019 Financials Reported; Several Catalysts for 2020; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
FDA Accepts Sacituzumab Filing; Reiterate Buy; Raising PT to $31
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Sacituzumab Govitecan Filing Resubmitted; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
3Q19 Financials Reported; Still Anticipating 2Q20 Sacituzumab Launch; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Bladder Cancer and Corporate Updates at ESMO; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R